11:25:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning BONEX 0.00 SEK
2024-05-16 Årsstämma 2024
2024-04-25 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning BONEX 0.00 SEK
2023-05-17 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning BONEX 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-04 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning BONEX 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning BONEX 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-08 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning BONEX 0.00 SEK
2019-05-14 Årsstämma 2019
2019-05-02 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-23 Ordinarie utdelning BONEX 0.00 SEK
2018-05-22 Årsstämma 2018
2018-05-04 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-02 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Bonesupport är verksamt inom medicinteknik. Bolaget utvecklar och kommersialiserar injicerbara biokeramiska bengraftsubstitut som ombildas till patientens eget ben och har förmåga att frisätta läkemedel. Bolagets bengraftsubstitut är baserade på teknologiplattformen Cerament. I dagsläget genomför bolaget löpande kliniska studier. Bolaget innehar försäljning i Europa och Nordamerika och huvudkontoret ligger i Lund.
2022-12-09 14:15:00

Pursuant to the authorization granted by the annual general meeting on 19 May 2022, the board of directors of BONESUPPORT HOLDING AB (”BONESUPPORT”) has resolved to issue and immediately thereafter repurchase 639,572 series C shares. The shares are issued and repurchased to secure delivery of shares for the share saving program LTI 2021, which was adopted by the 2021 annual general meeting and thereby replaces the share swap resolved by the same annual general meeting.

Pursuant to the authorization granted by the annual general meeting on 19 May 2022, the board of directors of BONESUPPORT has resolved to issue 639,572 series C shares to Skandinaviska Enskilda Banken AB. The subscription price per share amounts to SEK 0.625, which corresponds to the quota value of the shares. Furthermore, the board of directors has resolved to immediately repurchase all 639,572 series C shares from Skandinaviska Enskilda Banken AB at a price corresponding to the subscription price.

The purpose of the issue and the repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of performance shares to employees within the BONESUPPORT group who are participating in the share saving program LTI 2021, which was adopted by the annual general meeting on 20 May 2021, which means that the issue of series C shares replaces the share swap resolved by the same annual general meeting. Allotment of performance shares shall take place within 30 days from the publication of the year-end report for the financial year 2023.

Since previously, BONESUPPORT holds 1,002,866 own series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.

This information was submitted for publication, through the agency of the contact persons set out below, at 14:15 CET on 9 December 2022.